Special Issue

Mathematical Models of Cellular Immunotherapies in Cancer

Message from the Guest Editors

Cellular therapies in cancer constitute an emerging field including many different therapeutic strategies. Many of these strategies typically work by collecting a specific set of cells from patients, modifying them to produce some kind of attack on a patient's cancer cells, and then reinjecting them into the patient. Some examples are tumor-infiltrating lymphocytes, engineered T-cell receptor, chimeric antigen receptor (CAR)-T cells, cytotoxic T lymphocytes, natural killer cells, and mesenchymal stem cells. In this Special Issue, we plan to address cellular therapies from a mathematical and computational modeling perspective. Mathematical modeling has the potential to help in finding optimal administration protocols, provide a deeper understanding of the mechanisms and dynamics, help in the design of new clinical trials, and more. Despite the immense potential of these treatments, applied mathematicians and computational modelers have started to study these processes only very recently.

Guest Editors

Prof. Dr. Víctor M. Pérez-García

Prof. Dr. Lisette de Pillis

Dr. Philipp Altrock

Dr. Russell Rockne

Deadline for manuscript submissions

closed (31 May 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/54829

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)